Herpes Labialis Clinical Trial
Official title:
A Phase II, Randomized, Double-Blind, Parallel Group, Acyclovir-Controlled Study to Evaluate ZEP-3 Ointment for the Treatment of Cold Sores (Herpes Labialis).
Verified date | April 2018 |
Source | Shulov Innovate for Science Ltd. 2012 |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase II, prospective, randomized, double-blind, parallel group, acyclovir-controlled clinical study to evaluate the safety, tolerability and preliminary therapeutic efficacy of ZEP-3 ointment 1.0% for the treatment of cold sores (Herpes labialis), following five consecutive treatment days with five times daily topical administration.
Status | Completed |
Enrollment | 210 |
Est. completion date | June 24, 2018 |
Est. primary completion date | June 24, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: Prior to enrollment in this study, candidates must meet ALL of the following inclusion criteria: 1. Patients suffering from recurrent Herpes labialis with history of at least 3 cold sores recurrences during the previous 12 months. 2. Participants, either male or female are between 18 and 75 years of age. 3. Patients arrive at the clinic with any symptom of an acute Herpes labialis episode. Or, patients arrive at the clinic within 48 hours of treatment initiation for a recurrent Herpes labialis episode. 4. Patients with previous Herpes labialis episode must be healed for at least 14 days before baseline visit 5. Patients with no history of reaction to topical products. 6. Female subjects of childbearing potential must have a negative pregnancy test at screening and agree to use a proper contraceptive method during the study. 7. Participant understands the nature of the procedure and is willing and able to comply with all requirement of the protocol. 8. Patient is willing and able to provide written informed consent prior to any study procedure. Exclusion Criteria: 1. Subject has abnormal skin conditions or significant facial hair at or near the investigational area 2. Subject has any body piercing in or around the area ordinarily affected by cold sores. 3. Subjects with a history of cardiac abnormalities. 4. Subject has a recent history of renal dysfunction or serious hepatic disease 5. Subject has an active malignancy or immunodeficient disease 6. Subject who is unwilling to stop using topical medical, OTC, cosmetics or facial skin care products in or around the oral area during the study period. 7. Subject requires chronic use of immunomodifying drugs or topical steroids on or near the face. 8. Subject requires chronic use of anti-viral medication. 9. Subject requires chronic use of analgesics, pain medication or non-steroidal anti inflammatory agents (NSAIDs). 10. History of allergic or adverse response to acyclovir, or any related anti-viral drug. 11. Subject has had an infection with HSV-1 isolates know to be resistant to acyclovir, valacyclovir, famciclovir, or ganciclovir. 12. Subject has had a herpes vaccine. 13. Females during pregnancy, lactation or breastfeeding. 14. Subject has a history of alcoholism or drug abuse within the preceding 12 months. 15. Subject is currently enrolled in another clinical trial involving the use of a drug and/or a device. 16. Any history which, in the Investigator's judgment, makes the subject ineligible or places the subject at undue risk. 17. Subjects with immune deficiency conditions including acquired immune deficiency. |
Country | Name | City | State |
---|---|---|---|
Israel | Dermatology out-patients clinic, Lev Hayasmin MC | Netanya |
Lead Sponsor | Collaborator |
---|---|
Shulov Innovate for Science Ltd. 2012 |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinician-assessed "Time to healing" | Up to 14 days | ||
Secondary | Time for Herpes labialis recurrences | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00297011 -
Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis
|
Phase 2 | |
Completed |
NCT03310294 -
Immune Evidence to the Consumption of Lactobacillus GG and FOS Consumption in Patients With Herpes Labialis
|
N/A | |
Terminated |
NCT04539483 -
Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 1 Infection
|
Phase 2 | |
Completed |
NCT02265913 -
Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis
|
Phase 3 | |
Completed |
NCT01971385 -
Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis
|
Phase 1 | |
Active, not recruiting |
NCT01695187 -
NB-001 Treatment of Recurrent Herpes Labialis
|
Phase 3 | |
Completed |
NCT00375570 -
Safety Study of ME-609 for Treatment of Herpes Simplex Labialis in Adolescents
|
Phase 3 | |
Completed |
NCT02871492 -
Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes
|
Phase 2 | |
Completed |
NCT01484067 -
Study of a Cold Sore Patch for the Treatment of Herpes Labialis
|
N/A | |
Completed |
NCT00769314 -
Phase 3 Clinical Study for the Treatment of Cold Sore
|
Phase 3 | |
Completed |
NCT00878072 -
Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis
|
Phase 2/Phase 3 | |
Completed |
NCT01574612 -
Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old
|
Phase 3 | |
Completed |
NCT03661541 -
Immune Response and General Immune Health in Subjects Infected With Herpes Simplex Virus Type 1 (HSV-1)
|
Phase 1 | |
Recruiting |
NCT01306084 -
Viral Infections in Healthy and Immunocompromised Hosts
|
||
Terminated |
NCT03521479 -
A Phase 2, Muti-Center Study of Repeat Dosing of Squaric Acid Dibutyl Ester in Subjects With Herpes Labialis
|
Phase 2 | |
Terminated |
NCT00913692 -
A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis
|
Phase 2 | |
Completed |
NCT02207881 -
A Double-Blind, Randomized, Placebo-Controlled Study of Topical VDO for the Treatment of Herpes Simplex Labialis
|
Phase 2 | |
Completed |
NCT01653509 -
An Exploratory Study to Investigate the Inflammatory Response During a Cold Sore Episode
|
Phase 1 | |
Completed |
NCT00361881 -
Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis
|
Phase 3 | |
Recruiting |
NCT02582086 -
Study of a New Topical Natural Health Product for the Treatment of Herpes Labialis
|
N/A |